HomeCompareTXCB vs ABBV

TXCB vs ABBV: Dividend Comparison 2026

TXCB yields 100.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TXCB wins by $3.79M in total portfolio value
10 years
TXCB
TXCB
● Live price
100.00%
Share price
$2.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$3.90M
Annual income
$1,312,946.05
Full TXCB calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TXCB vs ABBV

📍 TXCB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTXCBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TXCB + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TXCB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TXCB
Annual income on $10K today (after 15% tax)
$8,500.00/yr
After 10yr DRIP, annual income (after tax)
$1,116,004.14/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TXCB beats the other by $1,094,948.14/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TXCB + ABBV for your $10,000?

TXCB: 50%ABBV: 50%
100% ABBV50/50100% TXCB
Portfolio after 10yr
$2.00M
Annual income
$668,858.90/yr
Blended yield
33.46%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TXCB
No analyst data
Altman Z
-4.2
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TXCB buys
0
ABBV buys
0
No recent congressional trades found for TXCB or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTXCBABBV
Forward yield100.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$3.90M$102.3K
Annual income after 10y$1,312,946.05$24,771.77
Total dividends collected$3.48M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TXCB vs ABBV ($10,000, DRIP)

YearTXCB PortfolioTXCB Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$20,700$10,000.00$11,550$430.00+$9.2KTXCB
2$41,495$19,345.79$13,472$627.96+$28.0KTXCB
3$80,643$36,243.16$15,906$926.08+$64.7KTXCB
4$152,116$65,828.38$19,071$1,382.55+$133.0KTXCB
5$278,813$116,048.53$23,302$2,095.81+$255.5KTXCB
6$497,119$198,789.52$29,150$3,237.93+$468.0KTXCB
7$863,169$331,251.38$37,536$5,121.41+$825.6KTXCB
8$1,461,129$537,538.09$50,079$8,338.38+$1.41MTXCB
9$2,413,798$850,390.15$69,753$14,065.80+$2.34MTXCB
10$3,895,710$1,312,946.05$102,337$24,771.77+$3.79MTXCB

TXCB vs ABBV: Complete Analysis 2026

TXCBStock

Cang Bao Tian Xia International Art Trade Center, Inc. operates a cultural service platform in China. It operates a platform for art investment and creating a model of online art exchanges and transactions, which allow collectors, artists, art dealers, and owners to access art trading market. The company also operates an online platform that enables its customers to buy, sell, store, and invest in various artworks, primarily antiques and modern paintings. The company was formerly known as Zhongchai Machinery, Inc. and changed its name to Cang Bao Tian Xia International Art Trade Center, Inc. in January 2019. Cang Bao Tian Xia International Art Trade Center, Inc. was founded in 1997 and is based in Haikou, China.

Full TXCB Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TXCB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TXCB vs SCHDTXCB vs JEPITXCB vs OTXCB vs KOTXCB vs MAINTXCB vs JNJTXCB vs MRKTXCB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.